Regeneron Pharmaceuticals (REGN) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free REGN Stock Alerts $980.16 +10.25 (+1.06%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 2 at 1:48 AM | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by BrokeragesJune 1 at 6:31 PM | marketbeat.comBOCHK Asset Management Ltd Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)BOCHK Asset Management Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,800 shares of the biopharmaceuMay 31 at 1:05 AM | globenewswire.comPress Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDMay 31 at 1:05 AM | globenewswire.comDupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDMay 31 at 1:00 AM | globenewswire.comPress Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationMay 31 at 1:00 AM | globenewswire.comUpdate on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationMay 30 at 5:40 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 30 at 9:21 AM | marketbeat.comTD Asset Management Inc Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)TD Asset Management Inc lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 43.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,513 shares of the biophaMay 30 at 7:38 AM | insidertrades.comMichael S. Brown Sells 1,172 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 29, 2024 | marketbeat.comTFO Wealth Partners LLC Has $1.03 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)TFO Wealth Partners LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 58,400.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,170 shares of the biopMay 29, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $1,142,535.92 in StockRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Michael S. Brown sold 1,172 shares of the firm's stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company's stock, valued at approximately $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.May 29, 2024 | prnewswire.comBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsMay 25, 2024 | marketbeat.comIntech Investment Management LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Intech Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 119.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,593 shares of the biophMay 25, 2024 | fool.com2 Biotech Stocks to Buy in MayMay 23, 2024 | globenewswire.comPromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCOMay 23, 2024 | businesswire.comMary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering FairMay 23, 2024 | marketbeat.comOntario Teachers Pension Plan Board Sells 995 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Ontario Teachers Pension Plan Board cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,971 shares ofMay 23, 2024 | marketbeat.comRegeneron Pharmaceuticals Q1 Earnings TranscriptMay 23, 2024 | fool.com3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 YearsMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 22, 2024 | finance.yahoo.comIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?May 21, 2024 | marketbeat.comDakota Wealth Management Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Dakota Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,372 shares of the biopharmaceutical companMay 20, 2024 | marketbeat.comAssetmark Inc. Acquires 1,552 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Assetmark Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,171 shares of the biopharmaceutical company's stockMay 20, 2024 | globenewswire.comDupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of MedicineMay 20, 2024 | globenewswire.comPress Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMMay 20, 2024 | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 19, 2024 | marketbeat.com1,061,803 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Norges BankNorges Bank bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,061,803 shares of the biopharmaceutical company's stock,May 19, 2024 | marketbeat.comING Groep NV Has $24.87 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)ING Groep NV reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,311 shares of the biopharmaceutical company's stock afMay 18, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 22,830 SharesMay 18, 2024 | msn.comRegeneron wins temporary restraining order preventing Eylea generic launch (update)May 17, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,019 shares of the biopharmaceMay 17, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells $22,355,820.90 in StockRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 22,830 shares of the company's stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The transaction was disclosed in a filing with the SEC, which is accessible through this link.May 17, 2024 | globenewswire.comMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024May 17, 2024 | insidertrades.comLeonard S. Schleifer Sells 25,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 16, 2024 | marketbeat.comBeacon Pointe Advisors LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Beacon Pointe Advisors LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,786 shares of the biopMay 16, 2024 | businesswire.comKirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)May 16, 2024 | fool.comThese 2 No-Brainer Growth Stocks Are Breaking New GroundMay 16, 2024 | fool.comThese 2 No-Brainer Growth Stocks Are Breaking New GroundMay 15, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 25,000 SharesRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company's stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is available through this link.May 15, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 242,350 shares oMay 14, 2024 | msn.comEvercore ISI Group Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Outperform RecommendationMay 14, 2024 | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Has $102.16 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,336 shares of the bMay 14, 2024 | seekingalpha.comRegeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)May 14, 2024 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (REGN)May 14, 2024 | marketbeat.comEvercore ISI Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday. They set an "outperform" rating and a $1,150.00 price target on the stock.May 13, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Trimmed by Almanack Investment Partners LLC.Almanack Investment Partners LLC. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,600 shares of the biopharmaceutiMay 13, 2024 | markets.businessinsider.comRegeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic RhinosinusitisMay 13, 2024 | globenewswire.comDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)May 12, 2024 | marketbeat.comDimensional Fund Advisors LP Reduces Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Dimensional Fund Advisors LP reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 593,522 shares of the biopharMay 11, 2024 | marketbeat.comTeacher Retirement System of Texas Sells 3,591 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Teacher Retirement System of Texas reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,967 shares of the biopharmaceutical company's stock after Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”. You just have to make this simple move before July 30, 2024. REGN Media Mentions By Week REGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.530.76▲Average Medical News Sentiment REGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼1415▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vertex Pharmaceuticals News GSK News Sanofi News Bristol-Myers Squibb News Zoetis News Takeda Pharmaceutical News Abbott Laboratories News Royalty Pharma News BeiGene News Catalent News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
